BioLineRx (BLRX) and Ayrmid, the parent company of Gamida Cell (GMDA), announced that the companies entered into a license agreement for motixafortide, BioLineRx’s FDA-approved stem cell mobilization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback